Search details
1.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell
; 174(3): 758-769.e9, 2018 07 26.
Article
in English
| MEDLINE | ID: mdl-30033370
2.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell
; 175(3): 889, 2018 10 18.
Article
in English
| MEDLINE | ID: mdl-30340047
3.
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Nature
; 608(7921): 199-208, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35859180
4.
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Prostate
; 84(8): 747-755, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38544345
5.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37951974
6.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 385(12): 1091-1103, 2021 09 16.
Article
in English
| MEDLINE | ID: mdl-34161051
7.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38126311
8.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(6): 597-610, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37269841
9.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36990608
10.
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Oncologist
; 28(5): e309-e312, 2023 05 08.
Article
in English
| MEDLINE | ID: mdl-36994854
11.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-32955174
12.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Article
in English
| MEDLINE | ID: mdl-32343890
13.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35131040
14.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Article
in English
| MEDLINE | ID: mdl-34246347
15.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med
; 381(1): 13-24, 2019 07 04.
Article
in English
| MEDLINE | ID: mdl-31150574
16.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Article
in English
| MEDLINE | ID: mdl-31157964
17.
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.
Invest New Drugs
; 40(2): 322-329, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34843005
18.
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Int J Urol
; 29(6): 533-540, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35293030
19.
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Cancer
; 127(12): 1965-1973, 2021 06 15.
Article
in English
| MEDLINE | ID: mdl-33690902
20.
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
J Urol
; 206(4): 914-923, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34039013